PT  - JOURNAL ARTICLE
AU  - Kenakin, Terry
TI  - Allostery: The Good, the Bad, and the Ugly
AID  - 10.1124/jpet.123.001838
DP  - 2024 Jan 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 110--120
VI  - 388
IP  - 1
4099  - http://jpet.aspetjournals.org/content/388/1/110.short
4100  - http://jpet.aspetjournals.org/content/388/1/110.full
SO  - J Pharmacol Exp Ther2024 Jan 01; 388
AB  - With the advent of functional screening, more allosteric molecules are being discovered and developed as possible therapeutic entities. Allosteric proteins are unique because of two specific properties: 1) separate binding sites for allosteric modulators and guests and 2) mandatory alteration of receptor conformation upon binding of allosteric modulators. For G protein–coupled receptors, these properties produce many beneficial effects on pharmacologic systems that are described here. Allosteric discovery campaigns also bring with them added considerations that must be addressed for the endeavor to be successful, and these are described herein as well.SIGNIFICANCE STATEMENT Recent years have seen the increasing presence of allosteric molecules as possible therapeutic drug candidates. The scientific procedures to characterize these are unique and require special techniques, so it is imperative that scientists understand the new concepts involved in allosteric function. This review examines the reasons why allosteric molecules should be considered as new drug entities and the techniques required to optimize the discovery process for allosteric molecules.